Passage Bio Inc expected to post a loss of $2.65 a share - Earnings Preview
Brief: Passage Bio And Remix Therapeutics Announce Merger Agreement
NASDAQ RESUMED AT 04:40 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:01 PM
Brief: Passage BIO - Terminates Research, Collaboration And License Agreement With Gemma BIO Therapeutics
U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis
U.S. STOCKS ON THE MOVE-Adobe, Biogen, Sable
U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO
Passage Bio slides after FDA calls for controlled trial of dementia gene therapy
U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen
Passage Bio rises as early‑stage data for rare dementia gene therapy shows promise
Passage Bio's 2025 net loss narrows
Passage Bio Q3 net loss narrows to $7.7 mln
Passage Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Passage Bio Inc expected to post a loss of $4.05 a share - Earnings Preview
Passage Bio Inc expected to post a loss of $4.05 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tesla, AbbVie, McDonald's
U.S. STOCKS ON THE MOVE-Copper miners, AMD, DallasNews
U.S. STOCKS ON THE MOVE-Huntington Ingalls, Nucor, Estee Lauder